TY - JOUR
T1 - Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting
T2 - A North American perspective: Executive summary
AU - Faxon, David P.
AU - Eikelboom, John W.
AU - Berger, Peter B.
AU - Holmes, David R.
AU - Bhatt, Deepak L.
AU - Moliterno, David J.
AU - Becker, Richard C.
AU - Angiolillo, Dominick J.
PY - 2011/10
Y1 - 2011/10
N2 - The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognized that "triple therapy" with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations, given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis, and major bleeding. This executive summary describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton pump inhibitors, and the use and duration of triple therapy after stent placement, based on the risk assessment.
AB - The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognized that "triple therapy" with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations, given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis, and major bleeding. This executive summary describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton pump inhibitors, and the use and duration of triple therapy after stent placement, based on the risk assessment.
KW - Antithrombotic therapy
KW - Atrial fibrillation
KW - Stent
KW - Triple therapy
KW - Warfarin
UR - http://www.scopus.com/inward/record.url?scp=82955229534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955229534&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.111.965186
DO - 10.1161/CIRCINTERVENTIONS.111.965186
M3 - Review article
C2 - 22010191
AN - SCOPUS:82955229534
SN - 1941-7640
VL - 4
SP - 522
EP - 534
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 5
ER -